Analystreport

Adaptimmune Therapeutics (NASDAQ:ADAP) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Adaptimmune Therapeutics plc - American Depositary Shares  (ADAP) 
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am Check Earnings Report